Summary of independent prognostic factors by multivariate regression results
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| aGVHD grade II-IV | |||
| HLA-DPB1 matched | 0.5 | 0.4-0.7 | <.001 |
| HLA-DPB1 mismatch nonpermissive, GVH | 1.4 | 1.05-1.8 | .02 |
| Major ABO mismatch with the use of PBSCs as the hematopoietic stem cell source | 1.3 | 1.03-1.8 | .03 |
| aGVHD grade III-IV | |||
| HLA-DPB1 mismatch nonpermissive, GVH with the use of PBSCs as the hematopoietic stem cell source | 3.1 | 1.8-5.2 | <.001 |
| Transplant-related mortality at 1 y | |||
| Major ABO mismatch with the use of PBSC as the hematopoietic stem cell source | 1.5 | 1.1-2.1 | .008 |
| Recipient age >55 y | 1.7 | 1.3-2.3 | <.001 |
| Disease progression at 3 y | |||
| BM recipient | 1.3 | 0.99-1.6 | .05 |
| Intermediate-risk group by DRI with the use HLA-DPB1–matched donor and PBSC as the hematopoietic stem cell source | 1.9 | 1.4-2.7 | <.001 |
| High and very high-risk group by DRI | 2.5 | 1.9-3.2 | <.001 |
| PFS at 3 y | |||
| Intermediate risk by DRI | 1.4 | 1.02-1.8 | .03 |
| High and very high risk by DRI | 2.4 | 1.8-3.2 | <.001 |
| Recipient age >55 y | 1.3 | 1.1-1.6 | .001 |
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| aGVHD grade II-IV | |||
| HLA-DPB1 matched | 0.5 | 0.4-0.7 | <.001 |
| HLA-DPB1 mismatch nonpermissive, GVH | 1.4 | 1.05-1.8 | .02 |
| Major ABO mismatch with the use of PBSCs as the hematopoietic stem cell source | 1.3 | 1.03-1.8 | .03 |
| aGVHD grade III-IV | |||
| HLA-DPB1 mismatch nonpermissive, GVH with the use of PBSCs as the hematopoietic stem cell source | 3.1 | 1.8-5.2 | <.001 |
| Transplant-related mortality at 1 y | |||
| Major ABO mismatch with the use of PBSC as the hematopoietic stem cell source | 1.5 | 1.1-2.1 | .008 |
| Recipient age >55 y | 1.7 | 1.3-2.3 | <.001 |
| Disease progression at 3 y | |||
| BM recipient | 1.3 | 0.99-1.6 | .05 |
| Intermediate-risk group by DRI with the use HLA-DPB1–matched donor and PBSC as the hematopoietic stem cell source | 1.9 | 1.4-2.7 | <.001 |
| High and very high-risk group by DRI | 2.5 | 1.9-3.2 | <.001 |
| PFS at 3 y | |||
| Intermediate risk by DRI | 1.4 | 1.02-1.8 | .03 |
| High and very high risk by DRI | 2.4 | 1.8-3.2 | <.001 |
| Recipient age >55 y | 1.3 | 1.1-1.6 | .001 |